JPWO2021094562A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021094562A5
JPWO2021094562A5 JP2022525171A JP2022525171A JPWO2021094562A5 JP WO2021094562 A5 JPWO2021094562 A5 JP WO2021094562A5 JP 2022525171 A JP2022525171 A JP 2022525171A JP 2022525171 A JP2022525171 A JP 2022525171A JP WO2021094562 A5 JPWO2021094562 A5 JP WO2021094562A5
Authority
JP
Japan
Prior art keywords
antigenic peptide
cell
antigenic
treatment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022525171A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501204A (ja
JP2023501204A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/082101 external-priority patent/WO2021094562A2/en
Publication of JP2023501204A publication Critical patent/JP2023501204A/ja
Publication of JPWO2021094562A5 publication Critical patent/JPWO2021094562A5/ja
Publication of JP2023501204A5 publication Critical patent/JP2023501204A5/ja
Pending legal-status Critical Current

Links

JP2022525171A 2019-11-15 2020-11-13 B細胞悪性腫瘍の予防及び治療のための抗原性ペプチド Pending JP2023501204A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19306475.5 2019-11-15
EP19306475 2019-11-15
EP2020079257 2020-10-16
EPPCT/EP2020/079257 2020-10-16
PCT/EP2020/082101 WO2021094562A2 (en) 2019-11-15 2020-11-13 Antigenic peptides for prevention and treatment of b-cell malignancy

Publications (3)

Publication Number Publication Date
JP2023501204A JP2023501204A (ja) 2023-01-18
JPWO2021094562A5 true JPWO2021094562A5 (https=) 2023-12-11
JP2023501204A5 JP2023501204A5 (https=) 2023-12-11

Family

ID=75911928

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525171A Pending JP2023501204A (ja) 2019-11-15 2020-11-13 B細胞悪性腫瘍の予防及び治療のための抗原性ペプチド

Country Status (19)

Country Link
US (2) US11759508B2 (https=)
EP (2) EP4357356A3 (https=)
JP (1) JP2023501204A (https=)
CN (1) CN114746112A (https=)
AU (1) AU2020384926B2 (https=)
BR (1) BR112022009100A2 (https=)
CA (2) CA3290212A1 (https=)
DK (1) DK4021487T5 (https=)
ES (1) ES2971929T3 (https=)
FI (1) FI4021487T3 (https=)
HR (1) HRP20240116T1 (https=)
HU (1) HUE065075T2 (https=)
LT (1) LT4021487T (https=)
MX (1) MX2022005704A (https=)
PL (1) PL4021487T3 (https=)
RS (1) RS65262B1 (https=)
SI (1) SI4021487T1 (https=)
SM (1) SMT202400048T1 (https=)
WO (1) WO2021094562A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102622188B1 (ko) 2016-10-07 2024-01-05 엔터롬 에스.에이. 암 치료를 위한 면역원성 화합물
WO2018065628A2 (en) 2016-10-07 2018-04-12 Enterome Microbiota sequence variants of tumor-related antigenic epitopes
US11478538B2 (en) 2016-10-07 2022-10-25 Enterome S.A. Immunogenic compounds for cancer therapy
CN112118863B (zh) 2018-04-11 2025-05-30 恩特罗姆公司 用于预防和治疗癌症的抗原肽
JP2025081784A (ja) * 2022-03-01 2025-05-28 bitBiome株式会社 アミノ酸残基配列を同定するための方法,プログラム及び記録媒体
JP2025526447A (ja) * 2022-07-29 2025-08-13 エルジー・ケム・リミテッド 抗原送達用組換え融合タンパク質およびその使用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
ES2275499T3 (es) 1999-03-19 2007-06-16 Glaxosmithkline Biologicals S.A. Vacuna contra streptococcus pneumoniae.
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
FR2798128B1 (fr) 1999-09-06 2001-11-16 Inst Nat Sante Rech Med Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla
WO2005007673A2 (en) * 2003-07-03 2005-01-27 Rush University Medical Center Immunogenic peptides
SI2119726T2 (en) 2008-05-14 2018-03-30 Immatics Biotechnologies Gmbh New and powerful Class II MHC peptides derived from survivin and neurocane
WO2013040142A2 (en) * 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
EP2797634A4 (en) 2011-12-29 2015-08-05 Moderna Therapeutics Inc MODIFIED MRNAS FOR THE CODING OF CELL-PENETRATING POLYPEPTIDES
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
EP3446119A1 (en) * 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
CN106008695A (zh) * 2016-06-19 2016-10-12 苏州普罗达生物科技有限公司 一种关于cd19免疫原多肽及其用途
KR102622188B1 (ko) * 2016-10-07 2024-01-05 엔터롬 에스.에이. 암 치료를 위한 면역원성 화합물
WO2019051001A1 (en) * 2017-09-06 2019-03-14 California Institute Of Technology SIGNALING AND BIFUNCTIONAL RECEPTORS HAVING ANTIGENS (SABR)
WO2019072871A2 (en) * 2017-10-09 2019-04-18 Enterome S.A. MICROBIOTIC SEQUENCE VARIANTS OF ANTIGENIC EPITOPES ASSOCIATED WITH A TUMOR
CN112118863B (zh) * 2018-04-11 2025-05-30 恩特罗姆公司 用于预防和治疗癌症的抗原肽
WO2020072700A1 (en) * 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines

Similar Documents

Publication Publication Date Title
EP1659179B1 (en) Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
JP5230579B2 (ja) 癌抑制遺伝子wt1の産物に基づく癌抗原
JP4227407B2 (ja) ワクチン組成物
JP2002514658A (ja) β−アミロイド前駆体タンパク質およびユビキチンBのフレームシフト変異体ならびにその使用
JP2008222721A6 (ja) ワクチン組成物
JP2012500001A5 (https=)
JP2003510334A (ja) 癌及び感染症の予防及び治療のためのストレスタンパク質組成物及び方法
JP2011522777A5 (https=)
JPWO2021163438A5 (https=)
JPWO2021094562A5 (https=)
JP2012506235A5 (https=)
JP2012513742A5 (https=)
JP2012510794A5 (https=)
WO2023163094A1 (ja) 成人t細胞白血病の治療又は予防のための医薬組成物
WO2023049921A1 (en) Pd-l1 inhibitory peptide for cancer immunotherapy
Melief et al. The Promise of T Cell Immunotherapy of Cancer
EP1436002A1 (en) Use of peptide vectors to improve the immune response to antigens
AU2002340561A1 (en) Use of peptide vectors to improve the immune response to antigens
HK1093521B (en) Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
HK1033838B (en) Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
HK1093522B (en) A process for the purification or production of a mage protein
HK1083026B (en) Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with t-helper epitopes and of compositions for vaccination
HK1110082A (en) Truncated lhrh formulations